Cargando…
MicroRNAs in B-cells: from normal differentiation to treatment of malignancies
MicroRNAs (miRNAs) are small non-coding RNAs that play important post-transcriptional regulatory roles in a wide range of biological processes. They are fundamental to the normal development of cells, and evidence suggests that the deregulation of specific miRNAs is involved in malignant transformat...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381575/ https://www.ncbi.nlm.nih.gov/pubmed/25622103 |
_version_ | 1782364474888421376 |
---|---|
author | Marques, Sara Correia Laursen, Maria Bach Bødker, Julie Støve Kjeldsen, Malene Krag Falgreen, Steffen Schmitz, Alexander Bøgsted, Martin Johnsen, Hans Erik Dybkaer, Karen |
author_facet | Marques, Sara Correia Laursen, Maria Bach Bødker, Julie Støve Kjeldsen, Malene Krag Falgreen, Steffen Schmitz, Alexander Bøgsted, Martin Johnsen, Hans Erik Dybkaer, Karen |
author_sort | Marques, Sara Correia |
collection | PubMed |
description | MicroRNAs (miRNAs) are small non-coding RNAs that play important post-transcriptional regulatory roles in a wide range of biological processes. They are fundamental to the normal development of cells, and evidence suggests that the deregulation of specific miRNAs is involved in malignant transformation due to their function as oncogenes or tumor suppressors. We know that miRNAs are involved in the development of normal B-cells and that different B-cell subsets express specific miRNA profiles according to their degree of differentiation. B-cell-derived malignancies contain transcription signatures reminiscent of their cell of origin. Therefore, we believe that normal and malignant B-cells share features of regulatory networks controlling differentiation and the ability to respond to treatment. The involvement of miRNAs in these processes makes them good biomarker candidates. B-cell malignancies are highly prevalent, and the poor overall survival of patients with these malignancies demands an improvement in stratification according to prognosis and therapy response, wherein we believe miRNAs may be of great importance. We have critically reviewed the literature, and here we sum up the findings of miRNA studies in hematological cancers, from the development and progression of the disease to the response to treatment, with a particular emphasis on B-cell malignancies. |
format | Online Article Text |
id | pubmed-4381575 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-43815752015-04-09 MicroRNAs in B-cells: from normal differentiation to treatment of malignancies Marques, Sara Correia Laursen, Maria Bach Bødker, Julie Støve Kjeldsen, Malene Krag Falgreen, Steffen Schmitz, Alexander Bøgsted, Martin Johnsen, Hans Erik Dybkaer, Karen Oncotarget Review MicroRNAs (miRNAs) are small non-coding RNAs that play important post-transcriptional regulatory roles in a wide range of biological processes. They are fundamental to the normal development of cells, and evidence suggests that the deregulation of specific miRNAs is involved in malignant transformation due to their function as oncogenes or tumor suppressors. We know that miRNAs are involved in the development of normal B-cells and that different B-cell subsets express specific miRNA profiles according to their degree of differentiation. B-cell-derived malignancies contain transcription signatures reminiscent of their cell of origin. Therefore, we believe that normal and malignant B-cells share features of regulatory networks controlling differentiation and the ability to respond to treatment. The involvement of miRNAs in these processes makes them good biomarker candidates. B-cell malignancies are highly prevalent, and the poor overall survival of patients with these malignancies demands an improvement in stratification according to prognosis and therapy response, wherein we believe miRNAs may be of great importance. We have critically reviewed the literature, and here we sum up the findings of miRNA studies in hematological cancers, from the development and progression of the disease to the response to treatment, with a particular emphasis on B-cell malignancies. Impact Journals LLC 2014-12-10 /pmc/articles/PMC4381575/ /pubmed/25622103 Text en Copyright: © 2015 Marques et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Review Marques, Sara Correia Laursen, Maria Bach Bødker, Julie Støve Kjeldsen, Malene Krag Falgreen, Steffen Schmitz, Alexander Bøgsted, Martin Johnsen, Hans Erik Dybkaer, Karen MicroRNAs in B-cells: from normal differentiation to treatment of malignancies |
title | MicroRNAs in B-cells: from normal differentiation to treatment of malignancies |
title_full | MicroRNAs in B-cells: from normal differentiation to treatment of malignancies |
title_fullStr | MicroRNAs in B-cells: from normal differentiation to treatment of malignancies |
title_full_unstemmed | MicroRNAs in B-cells: from normal differentiation to treatment of malignancies |
title_short | MicroRNAs in B-cells: from normal differentiation to treatment of malignancies |
title_sort | micrornas in b-cells: from normal differentiation to treatment of malignancies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381575/ https://www.ncbi.nlm.nih.gov/pubmed/25622103 |
work_keys_str_mv | AT marquessaracorreia micrornasinbcellsfromnormaldifferentiationtotreatmentofmalignancies AT laursenmariabach micrornasinbcellsfromnormaldifferentiationtotreatmentofmalignancies AT bødkerjuliestøve micrornasinbcellsfromnormaldifferentiationtotreatmentofmalignancies AT kjeldsenmalenekrag micrornasinbcellsfromnormaldifferentiationtotreatmentofmalignancies AT falgreensteffen micrornasinbcellsfromnormaldifferentiationtotreatmentofmalignancies AT schmitzalexander micrornasinbcellsfromnormaldifferentiationtotreatmentofmalignancies AT bøgstedmartin micrornasinbcellsfromnormaldifferentiationtotreatmentofmalignancies AT johnsenhanserik micrornasinbcellsfromnormaldifferentiationtotreatmentofmalignancies AT dybkaerkaren micrornasinbcellsfromnormaldifferentiationtotreatmentofmalignancies |